Kelly Gold, Chief Financial Officer at Camp4 Therapeutics Corp (CAMP), bought 6,551 shares at $1.65 ($11K) on 2026-08-03, disclosed to the SEC on 2026-08-05.
CFO Kelly Gold purchased $10,809 worth of shares at $1.65, marking the largest insider purchase in the company's history and occurring just days after a strong Q2 earnings beat. This high-level conviction buy suggests management believes the stock is undervalued despite recent volatility.
The stock has surged 22.68% over the last five days, recovering from a 5.62% decline over the past month, but remains down 4.62% year-to-date and is trading 48% below its 52-week high of $7.75.
1) Q2 earnings on August 13, 2026, where the company beat revenue estimates by 31.78%; 2) The company's gene-upregulation ASO platform update and SYNGAP1 clinic entry target in the second half of 2026; 3) A Zacks Rank #5 (Strong Sell) rating issued on July 16, 2026, which may present a contrarian entry point.
The stock faces significant risk from its Zacks Rank #5 (Strong Sell) designation, which indicates strong pessimism from analysts, and the company's history of missing revenue estimates, having lagged by -22.19% in Q1 2026.
Something here stands out, but not much.
| Filing → |